- Details
- Ruchika Talwar hosts Joshua Cabral and Yaw Nyame to explore the impact of mental health disorders on prostate cancer care. Their study, "Inequities in Definitive Treatment for Localized Prostate Cancer Among Those With Clinically Significant Mental Health Disorders," used the Medicare database from 2004 to 2015. They found that 50% of US adults meet DSM-IV disorder criteria at some point, and ment...
|
- Details
- Neil Desai and Paul Nguyen discuss the integration of the Decipher® genomic biomarker in prostate cancer treatment. The conversation centers on two trials, NRG-GU009 and GU010, which utilize Decipher® genomic classifiers to tailor treatment intensity, particularly in hormonal therapy. Dr. Nguyen emphasizes the shift from traditional metrics like PSA and Gleason scores to more precise genomic class...
|
- Details
- Zach Klaassen converses with Matthew Cooperberg about findings from the EMBARK study, presented at ESMO and published in the New England Journal. The study focuses on the efficacy of enzalutamide (enza) plus leuprolide versus leuprolide alone in treating high-risk non-metastatic hormone-sensitive prostate cancer. Dr. Cooperberg notes the predictability of better efficacy with combination treatment...
|
- Details
- Aditya Bagrodia hosts Daniel Spratt to discuss the complexities of gene expression classifiers in prostate cancer. Dr. Spratt's team conducted a study involving over 50,000 patients to evaluate the interchangeability of three major gene classifiers: Decipher, Oncotype, and Polaris. Contrary to common belief, the study reveals that these tests are not functionally interchangeable, showing only mode...
|
- Details
- Daniel Spratt engages with Amar Kishan about the role of transcriptomic profiling and PSMA PET imaging in prostate cancer. Dr. Kishan discusses a study involving 18 trials and 12,500 patients, which suggests that extra-prostatic disease is often the driver of distant metastasis in high-risk patients. The study also explores the correlation between Decipher® scores and the risk of upstaging on PSMA...
|
- Details
- Phillip Koo interviews Ragu Ratnakumaran about the analysis of the PACE-B study. The study is a phase III international randomized control trial involving 874 patients with low to intermediate-risk prostate cancer. Dr. Ratnakumaran's analysis focuses on the association between acute and late genitourinary and gastrointestinal toxicities in two radiotherapy treatment arms: conventional or moderatel...
|
- Details
- In an interview with Matthew Cooperberg, Michael Leapman discusses his research on the use of genomic tests and imaging in prostate cancer and the resulting national practice patterns. Leapman found significant regional variation in the utilization of these tests, with areas rich in urologists and prostate cancer care showing higher adoption rates. He also observed a correlation between increased...
|
- Details
- John Davis, Professor of Urology, discusses the new Journal of Urology Open Plus with Phillip Koo. The journal aims to provide fully gold open access, making research freely accessible to all. It addresses the need for easily accessible research, especially for publicly funded projects. The concept of cascading allows submissions to be considered across multiple journals within the AUA. The focus...
|
- Details
- Matt Cooperberg interviews Sigrid Carlsson, Director of Research at MSK for Urology, on the evolution of prostate cancer screening policy and ongoing innovative trials. Carlsson, an integral member of the AUA's screening guideline panel, highlights the transition from the traditional DRE and PSA tests to a new era of risk-stratified screening, aiming to optimize the benefits of PSA testing while m...
|
- Details
- Matthew Cooperberg and Daniel Lin discuss the update to the American Urological Association's (AUA) prostate cancer screening guideline in this discussion. They highlight the collaborative effort involved in the guideline update, involving a large group of experts and reviewers. They compare the AUA's process with that of the National Comprehensive Cancer Network (NCCN) and discuss the systematic...
|
